https://www.nasdaq.com/press-release/biolinerx-provides-highlights-from-oral-presentation-delivered-at-the-63rd-american
https://www.nasdaq.com/press-release/biolinerx-announces-formation-of-immuno-oncology-scientific-advisory-board-sab-2021
https://www.nasdaq.com/press-release/biolinerx-reports-third-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-third-quarter-2021-results-on-november-18-2021-2021-11-12
https://www.nasdaq.com/press-release/biolinerx-announces-an-oral-presentation-and-three-poster-presentations-at-the-63rd
https://www.nasdaq.com/press-release/biolinerx-announces-positive-results-from-pharmacoeconomic-study-positioning
https://www.nasdaq.com/press-release/biolinerx-reports-second-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-second-quarter-2021-results-on-august-18-2021-2021-08-12
https://www.nasdaq.com/press-release/biolinerx-reports-first-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-first-quarter-2021-results-on-may-26-2021-2021-05-20
https://www.nasdaq.com/press-release/biolinerx-announces-positive-top-line-results-from-genesis-phase-3-trial-of
https://www.nasdaq.com/press-release/biolinerx-announces-presentation-at-2021-american-association-for-cancer-research
https://www.nasdaq.com/press-release/biolinerx-reports-year-end-2020-financial-results-and-provides-corporate-update-2021
https://www.nasdaq.com/press-release/biolinerx-to-report-annual-2020-results-on-february-23-2021-2021-02-17
https://www.nasdaq.com/press-release/biolinerx-announces-closing-of-%2434.5-million-bought-deal-offering-and-full-exercise
https://www.nasdaq.com/press-release/biolinerx-increases-previously-announced-bought-deal-offering-to-%2430-million-2021-01
https://www.nasdaq.com/press-release/biolinerx-announces-%2410-million-bought-deal-offering-2021-01-19
https://www.nasdaq.com/press-release/biolinerx-announces-final-results-from-phase-2a-combat-keynote-202-triple-combination
https://www.nasdaq.com/press-release/biolinerx-reports-third-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-announces-initiation-of-phase-1b-clinical-trial-in-patients-with-acute
https://www.nasdaq.com/press-release/biolinerx-to-report-third-quarter-2020-results-on-november-23-2020-2020-11-18
https://www.nasdaq.com/press-release/biolinerx-announces-positive-results-from-interim-analysis-of-genesis-phase-3-trial
https://www.nasdaq.com/press-release/biolinerx-announces-initiation-of-phase-2-clinical-trial-in-first-line-metastatic
https://www.nasdaq.com/press-release/biolinerx-achieves-enrollment-target-in-phase-3-genesis-trial-for-planned-interim
https://www.nasdaq.com/press-release/biolinerx-reports-second-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-second-quarter-2020-results-on-august-6-2020-2020-07-31
https://www.nasdaq.com/press-release/biolinerx-to-present-at-the-2020-biotech-showcase-2020-01-08
https://www.nasdaq.com/press-release/biolinerx-announces-updated-phase-2a-data-from-triple-combination-arm-of-combat
https://www.nasdaq.com/press-release/biolinerx-announces-preliminary-phase-2a-data-from-triple-combination-arm-of-combat
https://www.nasdaq.com/press-release/biolinerx-to-host-investor-and-analyst-breakfast-meeting-on-december-5-2019-in-new
https://www.nasdaq.com/press-release/biolinerx-reports-third-quarter-2019-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-third-quarter-2019-results-on-november-11-2019-2019-11-06
https://www.nasdaq.com/press-release/biolinerx-announces-bl-8040-in-combination-with-keytruda-shows-clinical-activity-in
https://www.nasdaq.com/press-release/biolinerx-presents-preclinical-data-from-triple-combination-of-bl-8040-anti-pd-1-and
https://www.nasdaq.com/press-release/biolinerx-to-present-two-posters-at-the-society-for-immunotherapy-of-cancer-sitc-2019
https://www.nasdaq.com/press-release/biolinerx-to-deliver-oral-presentation-at-esmo-immuno-oncology-congress-2019-2019-10
https://www.nasdaq.com/press-release/biolinerx-announces-dosing-of-first-patient-in-part-2-of-phase-1-2a-clinical-study
https://www.nasdaq.com/press-release/biolinerx-successfully-completes-dose-escalation-part-of-phase-1-2a-clinical-study
https://www.nasdaq.com/press-release/biolinerx-reports-second-quarter-2019-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/biolinerx-to-report-second-quarter-2019-results-on-august-6-2019-2019-07-30
